Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Shanghai Pharmaceuticals Holding Co ( (HK:2607) ).
Shanghai Pharmaceuticals Holding Co., Ltd. recently held its 2024 Annual General Meeting (AGM) in Shanghai, where key resolutions, including the approval of the 2024 Annual Report and the Report of the Board of Directors, were passed with overwhelming support. The AGM was conducted in compliance with relevant legal and regulatory requirements, and it saw participation from a significant number of shareholders, underscoring the company’s strong governance and stakeholder engagement.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$15.70 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
More about Shanghai Pharmaceuticals Holding Co
Shanghai Pharmaceuticals Holding Co., Ltd. is a major player in the pharmaceutical industry in China, focusing on the production and distribution of pharmaceutical products. The company operates with a significant market presence in both A Shares and H Shares, reflecting its broad shareholder base and influence in the market.
Average Trading Volume: 7,261,365
Technical Sentiment Signal: Hold
Current Market Cap: HK$65.18B
See more insights into 2607 stock on TipRanks’ Stock Analysis page.